医学
心脏外科
心胸外科
心房颤动
随机对照试验
安慰剂
不利影响
子群分析
荟萃分析
秋水仙碱
内科学
入射(几何)
外科
麻醉
物理
替代医学
病理
光学
作者
Frederick Berro Rivera,Sung Whoy,John Paul Aparece,Sathika Jariyatamkitti,Mamas A. Mamas
出处
期刊:Journal of Cardiovascular Pharmacology
[Ovid Technologies (Wolters Kluwer)]
日期:2024-03-01
卷期号:83 (3): 265-270
被引量:3
标识
DOI:10.1097/fjc.0000000000001533
摘要
Abstract: The role of colchicine for the prevention of postoperative atrial fibrillation (POAF) after cardiothoracic surgery is not well-established. We aimed to evaluate its potential in preventing POAF using data from randomized controlled trials (RCTs). A literature search was performed to identify studies reporting POAF as an outcome after cardiac or thoracic surgery in adult patients randomized to either colchicine or placebo. Primary outcome measured was incidence of POAF. Secondary outcomes included gastrointestinal (GI) adverse effects, sepsis, and length of stay. Subgroup analyses based on treatment durations and type of surgery were also performed, as well as regression analyses to control for covariates. We identified a total of 5377 patients (colchicine = 2,689, placebo = 2688). Although colchicine use was associated with a significantly reduced risk of POAF, risk of GI adverse effects were significantly higher. The rates of infection and length of stay were similar across the groups. Subgroup analyses showed that colchicine was effective for POAF prevention in cardiac surgery, but not in thoracic surgery. Prevention of POAF and incidence of GI adverse effects were similar in short-term and long-term colchicine treatment. Colchicine significantly reduces the incidence of POAF in patients undergoing cardiac surgery, but not in thoracic surgery.
科研通智能强力驱动
Strongly Powered by AbleSci AI